Promotion deal is huge boost for Exact – but Pfizer must deliver
Pfizer is to push Exact’s cancer test in a deal that could “permanently alter the trajectory of Cologuard”.
Smaller medtechs soar in ’17 but could now be too expensive
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.